Search results for "LET"

showing 10 items of 23489 documents

Evaluation of efficacy and biocompatibility of a new absorbable synthetic substitute as a dural onlay graft in a large animal model.

2016

Numerous dura substitutes are commercially available, but no absorbable synthetic dura repair product has been used for both onlay and suture applications.The safety and effectiveness of a new absorbable synthetic substitute composed of Poly-L-lactide microfibers as onlay dural graft were evaluated.Physical properties and performance of the microfibrous synthetic dural substitute implanted as an onlay or suturable grafts were compared with these commercial products, including CODMAN ETHISORB™ Dura Patch and DuraGen™ Dural Graft Matrix, in a canine duraplasty model. The cerebrospinal fluid (CSF) leakage, macroscopic and microscopic observation at 30 and 90 days after implantation were invest…

musculoskeletal diseasesmedicine.medical_specialtyTime FactorsBiocompatibilityPolyesters02 engineering and technologyDural graftIn Vitro Techniques03 medical and health sciences0302 clinical medicineDogsDural substitutemedicineAnimalsCsf leakageCerebrospinal Fluid Leakbusiness.industryGeneral Medicine021001 nanoscience & nanotechnologynervous system diseasesSurgeryMicroscopic observationDisease Models AnimalNeurologyInlaysNeurology (clinical)Dura Mater0210 nano-technologybusiness030217 neurology & neurosurgeryLarge animalNeurological research
researchProduct

Is time to joint replacement a valid outcome measure in clinical trials of drugs for osteoarthritis?

2003

The rate of radiographic joint space narrowing is commonly used today as a structural outcome measure in clinical trials evaluating potential disease-modifying drugs in patients with hip osteoarthritis, but this results in a continuous variable. Among the methods proposed to circumvent this problem, it has been suggested that the incidence of total hip arthoplasty (THA) provides a hard outcome measure. It is a dichotomized variable, easy to measure and sensitive to change, with acceptable intrinsic validity. However, because this measure is limited by the variability of factors underlying the decision to perform surgery and the length of waiting lists, it has been suggested that time to ful…

musculoskeletal diseasesmedicine.medical_specialtyTime FactorsJoint replacementEndpoint Determinationmedicine.medical_treatmentArthroplasty Replacement HipInternational CooperationMeasure (physics)OsteoarthritisContinuous variableRheumatologyReference ValuesArthropathyOsteoarthritismedicineHumansClinical Trials as Topicbusiness.industryIncidence (epidemiology)Outcome measuresmedicine.diseaseClinical trialTreatment OutcomePhysical therapybusinessRheumatic diseases clinics of North America
researchProduct

MINIMIZING INFLIXIMAB TOXICITY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE

2008

Abstract Background Infliximab is a widely used biological agent for the treatment of inflammatory bowel disease, and has a favorable risk/benefit ratio. Aim It is useful to know that patients treated with infliximab are exposed to developing adverse events that could be reduced with a prudent and a rational clinical approach and by optimizing the treatment protocol. Methods PubMed (including Epub) was searched in October 2006 and again in March 2007. Results The high immunogenic potential of infliximab determines the antibodies that inhibit the effect of infliximab and the appearance of subsequent acute and delayed infusion reactions. Infliximab has an immunomodulatory effect, thus increas…

musculoskeletal diseasesmedicine.medical_specialtyTuberculosisInflammatory bowel diseaseGastroenterologyDrug Administration SchedulePharmacotherapyimmune system diseasesInternal medicinemedicineHumansImmunologic Factorsskin and connective tissue diseasesAdverse effectClinical Trials as TopicHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAntibodies Monoclonalmedicine.diseaseInflammatory Bowel DiseasesInfliximabInfliximabLymphomastomatognathic diseasesHeart failureToxicityDrug Therapy CombinationbusinessImmunosuppressive Agentsmedicine.drug
researchProduct

Orbital Decompression for Endocrine Ophthalmopathy: The Endonasal Approach

1994

A surgical endonasal procedure is described to perform orbital decompression in patients suffering from ophthalmopathy in Grave's disease. The decompression technique employs removal of the lamina papyracea as an exclusive modality or in conjunction with a transmaxillary or lateral decompression approach. This present series contain 23 patients who underwent decompression over a 3-year period and were followed for at least 6 months postoperative. The results of decompression were assessed by measuring reduction in proptosis and visual acuity. All patients demonstrated improved visual acuity. Measuring retroplacement of the globe, the endonasal approach proved to equal the results obtained …

musculoskeletal diseasesmedicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryDecompressionmedicine.medical_treatmentOrbital decompressionmedicine.diseaseeye diseasesSurgeryOptic neuropathy03 medical and health sciences0302 clinical medicineOtorhinolaryngology030220 oncology & carcinogenesismedicineIn patientEndocrine ophthalmopathymedicine.symptom030223 otorhinolaryngologyTraining programbusinessReduction (orthopedic surgery)American Journal of Rhinology
researchProduct

Patient-specific computational evaluation of stiffness distribution in ascending thoracic aortic aneurysm

2021

Quantifying local aortic stiffness properties in vivo is acknowledged as essential to assess the severity of an ascending thoracic aortic aneurysm (ATAA). Recently, the LESI (local extensional stiffness identification) methodology has been established to quantify non-invasively local stiffness properties of ATAAs using electrocardiographic-gated computed tomography (ECG-gated CT) scans. The aim of the current study was to determine the most sensitive markers of local ATAA stiffness estimation with the hypothesis that direct measures of local ATAA stiffness could better detect the high-risk patients. A cohort of 30 patients (12 BAV and 18 TAV) referred for aortic size evaluation by ECG-gated…

musculoskeletal diseasesmedicine.medical_specialtyanimal structuresBicuspid aortic valveExtensional stiffness0206 medical engineeringBiomedical EngineeringBiophysicsHemodynamicsmacromolecular substances02 engineering and technologyPositive correlationThoracic aortic aneurysm03 medical and health sciencesVascular Stiffness0302 clinical medicineBicuspid aortic valveInternal medicinemedicineHumansOrthopedics and Sports MedicineAortic Pulse PressureAortaComputingMilieux_MISCELLANEOUSShear stressAortic Aneurysm Thoracicbusiness.industryRehabilitationHemodynamics[SPI.MECA.BIOM]Engineering Sciences [physics]/Mechanics [physics.med-ph]/Biomechanics [physics.med-ph]StiffnessPatient specificAscending thoracic aortic aneurysmmedicine.diseaseNoninvasive inverse method020601 biomedical engineeringAortic AneurysmAortic ValveCardiologyAortic stiffnessmedicine.symptombusiness030217 neurology & neurosurgeryJournal of Biomechanics
researchProduct

Das rachitische X-Bein im Kindesalter

2003

Knee malpositions, for example valgus or varus deformations or flexion contractures, were often cited in the historical literature. In earlier times, clinical pictures such as rickets were often the reason for this kind of deformity. A causal therapy did not exist until the twentieth century. In most cases of rickets, genu valgum was reported as the typical knee deformation. The differential diagnosis for genu valgum caused by rickets was genu valgum traumaticum, paralyticum, and inflammatorium. The most important reports on the pathogenesis of valgus deformation can be found in publications by Hueter and von Mikulicz. The causal therapy of rickets was introduced at the beginning of the twe…

musculoskeletal diseasesmedicine.medical_specialtybiologySports medicinebusiness.industryRicketsKnock kneesmedicine.diseasebiology.organism_classificationAsepsisSurgeryGenu ValgumValgusOrthopedic surgerymedicineDeformityOrthopedics and Sports Medicinemedicine.symptombusinessDer Orthop�de
researchProduct

Association between lower extremity muscular strength and acute knee injuries in young team‐sports athletes

2020

The purpose of this study was to investigate LE muscular strength variables as potential risk factors for all and non‐contact acute knee and ACL injuries in young athletes. A total of 188 young (≤21) male and 174 female basketball and floorball players participated in LE muscular strength tests and were followed up to three years. The strength test battery consisted of 1RM leg press, maximal concentric isokinetic (60°/s) quadriceps and hamstrings and maximal isometric hip abductor strength. The outcomes were a new acute knee or ACL injury and a new acute non‐contact knee or ACL injury. A total of 51 (17 in males and 34 in females) new acute knee injuries registered and 17 (one in males and …

musculoskeletal diseasesmedicine.medical_specialtybiologyTeam sportbusiness.industryAthletesinjurypolvetligament Injury riskriskitekijätmusculoskeletal systembiology.organism_classificationPhysical strengthmusculoskeletal systemPeer reviewPhysical therapyMedicinevammatbusinessKnee injuriesAssociation (psychology)human activitieslihasvoimaurheilijat
researchProduct

Levetiracetam‐induced pediatric toxic epidermal necrolysis successfully treated with etanercept

2020

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

musculoskeletal diseasesmedicine.medical_specialtybiologybusiness.industryDermatologymedicine.diseaseDermatologyToxic epidermal necrolysisInfliximabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatrics Perinatology and Child Healthbiology.proteinmedicineTumor necrosis factor alphaLevetiracetamAntibodyskin and connective tissue diseasesbusinessmedicine.drugPediatric Dermatology
researchProduct

Treatment of Combined Medial and Lateral Collateral Ligament Insufficiency

2016

The medial and lateral collateral ligament complexes represent primary elbow ligament stabilizers. Injury to these structures may occur because of an elbow dislocation or due to a severe varus or valgus force. Most elbow dislocations are stable once reduced and may be treated conservatively. However, if the elbow remains unstable surgical treatment is recommended. Repair should be anatomical and should restore stability to the elbow in order to permit an early active range of motion. Reconstruction may be required in severe cases and where primary repair is not possible. Depending on the degree of instability, either one or both of the collateral ligament complexes may need to be repaired o…

musculoskeletal diseasesmedicine.medical_specialtybiologybusiness.industryElbowmusculoskeletal systembiology.organism_classificationSurgerybody regionsValgusPrimary repairmedicine.anatomical_structureElbow dislocationelbow instability elbow ligament reconstruction circumferential graft reconstructionSettore MED/33 - Malattie Apparato LocomotoreLigamentMedicinebusinessSurgical treatmentRange of motion
researchProduct

OP0015 Induction of remission and maintenance in early, aggressive rheumatoid arthritis using adalimumab in combination with methotrexate with or wit…

2017

Background Remission is the current aim of early RA treatment. In patients with early, aggressive RA, combination with adalimumab (ADA) plus methotrexate (MTX) was superior to either MTX or ADA alone in obtaining clinical remission. Moreover, it has been demonstrated that a short-term aggressive treatment with high-dose glucocorticoids (GC) plus conventional DMARDs lead to long-term (up to 5 years) benefits. Objectives To compare the proportion of patients who achieve remission at 12 months, between two groups of subjects treated with ADA + MTX + high dose GC (intensive) and ADA + MTX + placebo (standard), and to evaluate the proportion of those maintaining remission at 24 months, after dis…

musculoskeletal diseasesmedicine.medical_specialtybusiness.industry030503 health policy & servicesmedicine.diseasePlaceboGastroenterologyDiscontinuationFirst line treatmentDouble blind study03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisoneRheumatoid arthritisInternal medicinemedicineAdalimumabMethotrexate030212 general & internal medicine0305 other medical sciencebusinessmedicine.drug
researchProduct